Search results
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average of $2.39
ETF DAILY NEWS· 6 hours agoArbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.39 and ...
Hepatitis B is globally underassessed and undertreated, especially among women and Asian minorities...
Medical Xpress· 1 day agoNew evidence reveals global underassessment and undertreatment of chronic hepatitis B (HBV),...
Call for Experts: Regional Validation Committee (RVC) on the Elimination of Mother-to-Child...
World Health Organization· 2 days agoThis “Call for experts” provides information about the advisory group in question, the expert profiles being sought, the process to express interest, and the process of selection. The global ...
81K Bay Area residents with hepatitis B, mostly AAPI: CDC
KRON via Yahoo News· 2 days agoSAN FRANCISCO (KRON)—City officials were on the steps of City Hall Tuesday to declare May National...
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
GuruFocus.com via Yahoo Finance· 20 hours agoCompany Overview Arbutus Biopharma Corp is at the forefront of developing innovative treatments for chronic Hepatitis B virus (cHBV) ...
Signaturefd LLC Purchases 725 Shares of Hologic, Inc. (NASDAQ:HOLX)
ETF DAILY NEWS· 4 days agoSignaturefd LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 58.8% during the fourth quarter, according to the company in its most recent Form 13F filing with ...
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 7 days agoThe top line also missed the Zacks Consensus Estimate of $476 million and our model estimate of $460...
These Are the Drugs America Is Running Short On
247wallst.com· 4 days agoDrug shortages in America are the result of supply line challenges, profit-based operations, and company closures.
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
Zacks via Yahoo Finance· 4 days agoOn ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock...
St. Joseph News-Press· 3 days agoSHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"),...